Literature DB >> 22958902

Loss of SUFU function in familial multiple meningioma.

Mervi Aavikko1, Song-Ping Li, Silva Saarinen, Pia Alhopuro, Eevi Kaasinen, Ekaterina Morgunova, Yilong Li, Kari Vesanen, Miriam J Smith, D Gareth R Evans, Minna Pöyhönen, Anne Kiuru, Anssi Auvinen, Lauri A Aaltonen, Jussi Taipale, Pia Vahteristo.   

Abstract

Meningiomas are the most common primary tumors of the CNS and account for up to 30% of all CNS tumors. An increased risk of meningiomas has been associated with certain tumor-susceptibility syndromes, especially neurofibromatosis type II, but no gene defects predisposing to isolated familial meningiomas have thus far been identified. Here, we report on a family of five meningioma-affected siblings, four of whom have multiple tumors. No NF2 mutations were identified in the germline or tumors. We combined genome-wide linkage analysis and exome sequencing, and we identified in suppressor of fused homolog (Drosophila), SUFU, a c.367C>T (p.Arg123Cys) mutation segregating with the meningiomas in the family. The variation was not present in healthy controls, and all seven meningiomas analyzed displayed loss of the wild-type allele according to the classic two-hit model for tumor-suppressor genes. In silico modeling predicted the variant to affect the tertiary structure of the protein, and functional analyses showed that the activity of the altered SUFU was significantly reduced and therefore led to dysregulated hedgehog (Hh) signaling. SUFU is a known tumor-suppressor gene previously associated with childhood medulloblastoma predisposition. Our genetic and functional analyses indicate that germline mutations in SUFU also predispose to meningiomas, particularly to multiple meningiomas. It is possible that other genic mutations resulting in aberrant activation of the Hh pathway might underlie meningioma predisposition in families with an unknown etiology.
Copyright © 2012 The American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22958902      PMCID: PMC3511996          DOI: 10.1016/j.ajhg.2012.07.015

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  28 in total

1.  Mammalian suppressor-of-fused modulates nuclear-cytoplasmic shuttling of Gli-1.

Authors:  P Kogerman; T Grimm; L Kogerman; D Krause; A B Undén; B Sandstedt; R Toftgård; P G Zaphiropoulos
Journal:  Nat Cell Biol       Date:  1999-09       Impact factor: 28.824

2.  Mutation of the PTEN (MMAC1) tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome arm 10q.

Authors:  J Boström; J M Cobbers; M Wolter; G Tabatabai; R G Weber; P Lichter; V P Collins; G Reifenberger
Journal:  Cancer Res       Date:  1998-01-01       Impact factor: 12.701

3.  A new germline mutation of the PTCH gene in a Japanese patient with nevoid basal cell carcinoma syndrome associated with meningioma.

Authors:  Genshu Tate; Min Li; Takao Suzuki; Toshiyuki Mitsuya
Journal:  Jpn J Clin Oncol       Date:  2003-01       Impact factor: 3.019

4.  Multiple meningiomas. Clinical and computer tomographic observations.

Authors:  H C Nahser; W Grote; E Löhr; L Gerhard
Journal:  Neuroradiology       Date:  1981       Impact factor: 2.804

5.  Amplification of the gli gene in childhood sarcomas.

Authors:  W M Roberts; E C Douglass; S C Peiper; P J Houghton; A T Look
Journal:  Cancer Res       Date:  1989-10-01       Impact factor: 12.701

6.  Suppressor of fused regulates Gli activity through a dual binding mechanism.

Authors:  Mark Merchant; Felix F Vajdos; Mark Ultsch; Henry R Maun; Ulrich Wendt; Jennifer Cannon; William Desmarais; Robert A Lazarus; Abraham M de Vos; Frederic J de Sauvage
Journal:  Mol Cell Biol       Date:  2004-10       Impact factor: 4.272

7.  Frequency and risk factors for meningioma in clinically healthy 75-year-old patients: results of the Transdanube Ageing Study (VITA).

Authors:  Wolfgang Krampla; Stephan Newrkla; Wolfgang Pfisterer; Susanne Jungwirth; Peter Fischer; Thomas Leitha; Walter Hruby; Karl Heinz Tragl
Journal:  Cancer       Date:  2004-03-15       Impact factor: 6.860

8.  Patched acts catalytically to suppress the activity of Smoothened.

Authors:  J Taipale; M K Cooper; T Maiti; P A Beachy
Journal:  Nature       Date:  2002-08-22       Impact factor: 49.962

9.  Mutations in SUFU predispose to medulloblastoma.

Authors:  Michael D Taylor; Ling Liu; Corey Raffel; Chi-chung Hui; Todd G Mainprize; Xiaoyun Zhang; Ron Agatep; Sharon Chiappa; Luzhang Gao; Anja Lowrance; Aihau Hao; Alisa M Goldstein; Theodora Stavrou; Stephen W Scherer; Wieslaw T Dura; Brandon Wainwright; Jeremy A Squire; James T Rutka; David Hogg
Journal:  Nat Genet       Date:  2002-06-17       Impact factor: 38.330

10.  Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine.

Authors:  J Taipale; J K Chen; M K Cooper; B Wang; R K Mann; L Milenkovic; M P Scott; P A Beachy
Journal:  Nature       Date:  2000-08-31       Impact factor: 49.962

View more
  53 in total

Review 1.  Unraveling the therapeutic potential of the Hedgehog pathway in cancer.

Authors:  Dereck Amakye; Zainab Jagani; Marion Dorsch
Journal:  Nat Med       Date:  2013-11-07       Impact factor: 53.440

2.  Targeted next-generation sequencing for differential diagnosis of neurofibromatosis type 2, schwannomatosis, and meningiomatosis.

Authors:  Camille Louvrier; Eric Pasmant; Audrey Briand-Suleau; Joëlle Cohen; Patrick Nitschké; Juliette Nectoux; Lucie Orhant; Cécile Zordan; Cyril Goizet; Stéphane Goutagny; Dominique Lallemand; Michel Vidaud; Dominique Vidaud; Michel Kalamarides; Béatrice Parfait
Journal:  Neuro Oncol       Date:  2018-06-18       Impact factor: 12.300

3.  Multisite interaction with Sufu regulates Ci/Gli activity through distinct mechanisms in Hh signal transduction.

Authors:  Yuhong Han; Qing Shi; Jin Jiang
Journal:  Proc Natl Acad Sci U S A       Date:  2015-05-04       Impact factor: 11.205

4.  Association of Genetic Predisposition With Solitary Schwannoma or Meningioma in Children and Young Adults.

Authors:  Omar N Pathmanaban; Katherine V Sadler; Ian D Kamaly-Asl; Andrew T King; Scott A Rutherford; Charlotte Hammerbeck-Ward; Martin G McCabe; John-Paul Kilday; Christian Beetz; Nicola K Poplawski; D Gareth Evans; Miriam J Smith
Journal:  JAMA Neurol       Date:  2017-09-01       Impact factor: 18.302

5.  Members of the Rusc protein family interact with Sufu and inhibit vertebrate Hedgehog signaling.

Authors:  Zhigang Jin; Tyler Schwend; Jia Fu; Zehua Bao; Jing Liang; Huimin Zhao; Wenyan Mei; Jing Yang
Journal:  Development       Date:  2016-09-15       Impact factor: 6.868

6.  Suppressor of fused impedes Ci/Gli nuclear import by opposing Trn/Kapβ2 in Hedgehog signaling.

Authors:  Qing Shi; Yuhong Han; Jin Jiang
Journal:  J Cell Sci       Date:  2014-01-10       Impact factor: 5.285

7.  Genetic profiling by single-nucleotide polymorphism-based array analysis defines three distinct subtypes of orbital meningioma.

Authors:  Cheng-Ying Ho; Stacy Mosier; Janice Safneck; Diva R Salomao; Neil R Miller; Charles G Eberhart; Christopher D Gocke; Denise A S Batista; Fausto J Rodriguez
Journal:  Brain Pathol       Date:  2014-05-21       Impact factor: 6.508

Review 8.  Molecular mechanisms of suppressor of fused in regulating the hedgehog signalling pathway.

Authors:  Dengliang Huang; Yiting Wang; Jiabin Tang; Shiwen Luo
Journal:  Oncol Lett       Date:  2018-03-01       Impact factor: 2.967

Review 9.  A Systematic Literature Review of Whole Exome and Genome Sequencing Population Studies of Genetic Susceptibility to Cancer.

Authors:  Alisa M Goldstein; Elizabeth M Gillanders; Melissa Rotunno; Rolando Barajas; Mindy Clyne; Elise Hoover; Naoko I Simonds; Tram Kim Lam; Leah E Mechanic
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-05-28       Impact factor: 4.254

Review 10.  Meningiomas from a developmental perspective: exploring the crossroads between meningeal embryology and tumorigenesis.

Authors:  Julien Boetto; Matthieu Peyre; Michel Kalamarides
Journal:  Acta Neurochir (Wien)       Date:  2020-11-20       Impact factor: 2.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.